Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
Chronic glomerular diseases, associated with renal failure and cardiovascular morbidity, represent a major health issue. However, they remain poorly understood. Here we have reported that tightly controlled mTOR activity was crucial to maintaining glomerular podocyte function, while dysregulation of mTOR facilitated glomerular diseases. Genetic deletion of mTOR complex 1 (mTORC1) in mouse podocytes induced proteinuria and progressive glomerulosclerosis. Furthermore, simultaneous deletion of both mTORC1 and mTORC2 from mouse podocytes aggravated the glomerular lesions, revealing the importance of both mTOR complexes for podocyte homeostasis. In contrast, increased mTOR activity accompanied human diabetic nephropathy, characterized by early glomerular hypertrophy and hyperfiltration. Curtailing mTORC1 signaling in mice by genetically reducing mTORC1 copy number in podocytes prevented glomerulosclerosis and significantly ameliorated the progression of glomerular disease in diabetic nephropathy. These results demonstrate the requirement for tightly balanced mTOR activity in podocyte homeostasis and suggest that mTOR inhibition can protect podocytes and prevent progressive diabetic nephropathy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gödel et al. [16] suggested that mTOR signaling plays a role in podocyte homeostasis.”
From A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I (2018) · cites this paper as [16]
In the citing paper
“The decrease in activity of neurofibromin in NF1 might also be associated with LPG which is a glomerular disease, and contribute to the development of LPG as an additional factor.”
From A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I (2018) · cites this paper as [16]
In the citing paper
“Although podocytes have high basal levels of autophagy, high mTORC1 activity is also required for these cells to maintain their function”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [51]
In the citing paper
“However, the side effects of long-term or complete mTORC1 inhibition in kidney cells have been well-recognized, such as the early onset of proteinuria caused by specific inhibition of mTORC1 activity in podocytes in mice and the disruption of kidney tubular homeostasis caused by specific inhibition of mTORC1 activity in kidney tubular cells in mice51,80.”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [51]
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Self-citationA global double-fluorescent Cre reporter mouse
Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., & Luo, L. (2007) · genesis · doi:10.1002/dvg.20335 · Cited by 3,491
Watterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
The unbiased estimation of number and sizes of arbitrary particles using the disector
Sterio, D. C. (1984) · Journal of Microscopy · doi:10.1111/j.1365-2818.1984.tb02501.x · Cited by 2,519
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Laplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
VEGF Inhibition and Renal Thrombotic Microangiopathy
Eremina, V., Jefferson, J. A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J., Richardson, C., Kopp, J. B., Kabir, M. G., Backx, P. H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707330 · Cited by 1,504
Holz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Research works printed but not linked: 5
- Estacio, 2001, Adv Intern Med., 46, 359
- Munivenkatappa, 2010, Histol Histopathol., 25, 189
- Weening, 1987, Am J Pathol., 129, 64
- Artacho-Perula, 1993, Lab Invest., 68, 56
- Souster, 1980, J Anat., 130, 595
Cited by
Items 401–500 of 553
Hua, R., Wei, J., Torres, M., He, Y., Li, Y., Sun, X., Wang, L., Inoki, K., & Yoshida, S. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.30996 · Cited by 9
Self-citationStridh, S., Palm, F., Takahashi, T., Ikegami‐Kawai, M., & Hansell, P. (2015) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2015.1062442 · Cited by 9
“All those events are partially prevented by rapamycin (30).”
Backgroundβ2-Adrenergic receptor agonists as a treatment for diabetic kidney disease
Arif, E., Medunjanin, D., Solanki, A. K., Zuo, X., Su, Y., Dang, Y., Winkler, B., Lerner, K., Kamal, A., Palygin, O., et al. (2023) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00254.2023 · Cited by 9
Constitutive activation of the mTOR signaling pathway within the normal glomerulus
McMahon, G. M., Datta, D. B., Bruneau, S., Kann, M., Khalid, M., Ho, J., Seto, T., Kreidberg, J. A., Stillman, I. E., & Briscoe, D. M. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.075 · Cited by 10
“Recent studies using knockout mice indicate that podocyte-specific interruption of mTORC1 function (via deletion of raptor) results in podocyte effacement, histological evidence of glomerular disease and proteinuria [15,34,35].”
BackgroundGlucagon receptor activation contributes to the development of kidney injury
Billeschou, A., Johansen, C. D., Galsgaard, K. D., Elmelund, E., Winther‐Sørensen, M., Holst, J. J., Albrechtsen, N. J. W., & Sørensen, C. M. (2024) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00088.2024 · Cited by 8
Approach to Studies on Podocyte Lesions Mediated by Hyperglycemia: A Systematic Review
Silva, J. S., Miguel, C. B., Felipe, A. G. B., Martins, A. L. M. D. S., Miguel, R. B., Carrijo, M. O., Mazurek, L., Araújo, L. S., da Silva, C. A., Goés‐Neto, A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188990 · Cited by 9
“…mTORC1 hyperactivation and proteostasis failure mislocalize slit-diaphragm proteins, induce ER-stress/EMT programs, and suppress autophagy; conversely, broad perturbation of mTOR signaling yields hypertrophy and effacement, illustrating a narrow homeostatic window for podocyte proteostasis [58,59].”
InfluentialSun, L.-Y., Sun, G.-Y., Nan, Y., Wang, H., Sun, Y., Shi, Y., Yang, Y., & Wang, Q.-F. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1778473 · Cited by 9
“Simultaneously, BCAA-mediated mTORC1 hyperactivation in podocytes suppresses autophagy and exacerbates insulin resistance, creating a metabolic milieu that potentiates toxin-induced injury (136, 149).”
Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition
Kronick, J., Gabril, M. Y., & House, A. A. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.04.016 · Cited by 8
Arsenic aggravates the progression of diabetic nephropathy through miRNA-mRNA-autophagy axis
Zhang, X., Sira, J., Liu, J., Li, J., Yang, Z., Sun, D., & Zhang, W. (2024) · Food and Chemical Toxicology · doi:10.1016/j.fct.2024.114628 · Cited by 8
TORCing up the Importance of Calcium Signaling
Lavin, P., & Winn, M. P. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011060595 · Cited by 8
Cimeno, A., Munley, J. A., Drachenberg, C. B., Weir, M. R., Haririan, A., Bromberg, J. S., Barth, R. N., & Scalea, J. R. (2018) · Clinical Transplantation · doi:10.1111/ctr.13425 · Cited by 8
Tabei, A., Sakairi, T., Hamatani, H., Ohishi, Y., Watanabe, M., Nakasatomi, M., Ikeuchi, H., Kaneko, Y., Kopp, J. B., & Hiromura, K. (2023) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00313.2022 · Cited by 9
Schell, C., Kretz, O., Bregenzer, A., Rogg, M., Helmstädter, M., Lisewski, U., Gotthardt, M., Tharaux, P., Huber, T. B., & Grahammer, F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129424 · Cited by 10
Self-citationTakasaki, S., Matsunaga, A., Joh, K., & Saito, T. (2018) · CEN Case Reports · doi:10.1007/s13730-018-0309-2 · Cited by 7
“[16] suggested that mTOR signaling plays a role in podocyte homeostasis.”
BackgroundDeletion of IRE1α in podocytes exacerbates diabetic nephropathy in mice
Cybulsky, A. V., Papillon, J., Guillemette, J., Navarro‐Betancourt, J. R., Chung, C.-F., Iwawaki, T., & Fantus, I. G. (2024) · Scientific Reports · doi:10.1038/s41598-024-62599-7 · Cited by 8
“In podocytes, diabetic metabolic changes were shown to perturb the balance between the UPR, autophagy and mTOR signaling 22,41,42 .”
Shi, C., Wang, X., Qin, S., He, A., Wu, X., Ke, Q., Shen, R., Wan, Y., Wang, L., Xiao, Y., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06519-y · Cited by 7
Li, J., Zhang, L., Yang, C., Yao, C., Xu, Y.-Z., Liu, H.-F., & An, N. (2026) · Autoimmunity · doi:10.1080/08916934.2025.2612417 · Cited by 7
Selective autophagy in kidney health and disease
Fu, Y. W., Livingston, M. J., Dong, G., Chen, A., Cai, J., & Dong, Z. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01082-0 · Cited by 9
“In podocytes, mTORC2 supports cytoskeletal adaptation under albuminuric challenge; podocyte-specific Rictor disruption increases the susceptibility to albumin overload-induced structural injury 155 . mTORC2 also fine-tunes cargo selection.”
Watany, M. M., El‐Horany, H. E., Elhosary, M. M., & Elhadidy, A. A. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00580-8 · Cited by 7
Chhuon, C., Herrera-Marcos, L. V., Zhang, S., Charrière‐Bertrand, C., Jung, V. A., Lipecka, J., Savas, B., Nasser, N., Pawlak, A., Boulmerka, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512124 · Cited by 8
“The aberrant activation of mTORC1 results in negative feedback to PI3K activation [70] and, in podocytes, it leads to cell injury, mimicking a feature of diabetic nephropathy [71,72].”
BackgroundWhy is chronic kidney disease progressive? Evolutionary adaptations and maladaptations
Chevalier, R. L. (2023) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00134.2023 · Cited by 12
A novel therapeutic target for kidney diseases: Lessons learned from starvation response
Yamahara, K., Yasuda‒Yamahara, M., & Kume, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108590 · Cited by 7
Chung, N. K. X., Metherall, P., McCormick, J., Simms, R., & Ong, A. C. M. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac037 · Cited by 7
“The underlying mechanisms by which everolimus slows TSC-associated eGFR decline however remain unclear but could include a direct effect on AML shrinkage or other cellular effects directly mediated by mTORC1 [37].”
Pathophysiology of Chronic Kidney Disease
Ren, J., & Dai, C. (2019) · Springer eBooks · doi:10.1007/978-981-32-9131-7_2 · Cited by 17
Yu Nu Compound Regulates Autophagy and Apoptosis Through mTOR in vivo and vitro
He, C., Liu, G., Zhuang, S., Zhang, J., Chen, Y., Li, H., Huang, Z., & Zheng, Y. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s253494 · Cited by 7
Understanding the Roles of Non-coding RNAs and Exosomal Non-Coding RNAs in Diabetic Nephropathy
Zhu, Y., Liu, C., & Hallajzadeh, J. (2024) · Current Molecular Medicine · doi:10.2174/0115665240287631240321072504 · Cited by 6
Ways and Means of Cellular Reconditioning for Kidney Regeneration
Ishiko, S., & Goligorsky, M. S. (2022) · American Journal of Nephrology · doi:10.1159/000522050 · Cited by 6
Rapamycin attenuated podocyte apoptosis via upregulation of nestin in Ang II-induced podocyte injury
Shi, H., Zhao, Y., He, T., Wen, X., Qu, G., Li, S., Gan, W., & Zhang, A. (2022) · Molecular Biology Reports · doi:10.1007/s11033-021-07029-x · Cited by 6
“A growing number of studies have shown that mTOR signaling pathway is an important member of maintaining podocyte homeostasis and tubelar transportation in renal diseases [21-22].”
BackgroundHigh-throughput data on circular RNA reveal novel insights into chronic glomerulonephritis
Gao, Y.-C., Jiang, N., Qin, X., Jiang, H., Wei, L., & Gao, J. (2022) · Genes & Genomics · doi:10.1007/s13258-022-01320-2 · Cited by 6
“For the circRNA-1327–miRNA–mRNA subnetwork, the GO terms were mainly enriched in the regulation of deacetylation, cell apoptosis, cell differentiation, fibrillar collagen and ECM structural constituents, while the pathways were mainly enriched in ECM–receptor interaction, FA, and the mTOR signaling pathway, which are…”
BackgroundVidigal, A. C., de Lucena, D. D., Beyerstedt, S., & Rangel, É. B. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2243808 · Cited by 6
Axelsson, J., Rippe, A., & Rippe, B. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00632.2014 · Cited by 6
Fawzy, M. S., Ageeli, E. A., Al‑Qahtani, S., Alsel, B. T. A., Kattan, S. W., Alelwani, W., & Toraih, E. A. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10985 · Cited by 6
“been implicated in maintaining the glomerular podocyte func‐ tion; increased activity contributed to glomerular hypertrophy and hyperfiltration associated with progressive DN (32).”
BackgroundDun, S., Wang, Y., Wan, L., Wang, Q., Lu, Q., Yang, X.-Y., Zhang, Q., Chen, H., Qiu, L.-P., & Zou, L. (2023) · World Journal of Pediatrics · doi:10.1007/s12519-023-00751-5 · Cited by 7
“Prior studies have also speculated that mTOR inhibitors may worsen chronic kidney disease [31, 32], but there is no conclusive evidence that mTOR inhibitors can exacerbate GFR decline.”
Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer
Guo, F. (2014) · Journal of Oncobiomarkers · doi:10.13188/2325-2340.1000008 · Cited by 7
“The critical role of mTOR is attested by the lethality of mice harboring full-body knockout of mTOR and by tissue-specific knockout of mTOR complex components [4-24].”
Up-regulated mTOR pathway indicates active disease in both human native and transplant kidneys.
Li, W., & Zhang, P. L. (2013) · PubMed · Cited by 6
Emerging Roles of Autophagy in the Stressed Kidney Allograft
Pallet, N. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.11.006 · Cited by 6
Pallet, N. (2017) · médecine/sciences · doi:10.1051/medsci/20173303014 · Cited by 6
The role of sirolimus in proteinuria in diabetic nephropathy rats.
Wang, J., Xu, Z., Chen, B., Zheng, S., Xia, P., & Cai, Y. (2017) · Europe PMC (PubMed Central) · doi:10.22038/ijbms.2017.9618 · Cited by 6
“proteinuria (30); and there’s evidence that both mTORC1 and mTORC2 are needed for podocyte development and podocyte maintenance, and mTOR function in podocytes is essential for the integrity of the filtration barrier (31).”
BackgroundEl‐Ashmawy, H. M., & Ahmed, A. M. (2019) · The Egyptian Journal of Internal Medicine · doi:10.4103/ejim.ejim_85_18 · Cited by 7
Grahammer, F., Benzing, T. R., & Huber, T. B. (2015) · Kidney International · doi:10.1038/ki.2015.5 · Cited by 6
Self-citationThe sclerosing glomerulus in mice and man
Mondini, A., Messa, P., & Rastaldi, M. P. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000444817.95496.40 · Cited by 6
“For example, in diabetic nephropathy, mTOR hyperactivity seems to be responsible for podocyte damage, glomerulosclerosis, and disease progression [28,29].”
BackgroundSelf-citationJeong, S. Y. (2025) · Cureus · doi:10.7759/cureus.96018 · Cited by 13
“Recent independent studies have revealed a role for mTOR signaling in podocyte function and diabetic nephropathy, suggesting that inhibiting mTOR could offer therapeutic benefits [112].”
Álamo-Martínez, J. M., Olivares, C., Barrera, L., Gómez, L. M. M., Suárez, G., Bellido, C. B., Serrano, J., Muntané, J., Ruiz, F. J. P., & Gómez‐Bravo, M. Á. (2015) · World Journal of Transplantation · doi:10.5500/wjt.v5.i1.19 · Cited by 5
Ogawa, S., Ishimura, T., Miyake, H., & Fujisawa, M. (2017) · International Journal of Urology · doi:10.1111/iju.13287 · Cited by 5
Liu, X., Mao, Z., Yuan, M., Li, L., Tan, Y. C. R. S., Qu, Z., Chen, M., & Yu, F. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2023-000896 · Cited by 5
Rapamycin treatment induces tubular proteinuria: role of megalin-mediated protein reabsorption
Peres, R. A. S., Peruchetti, D. B., Silva-Aguiar, R. P., Teixeira¹, D. E., Gomes, C. P., Takiya, C. M., Pinheiro, A. A. S., & Caruso‐Neves, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1194816 · Cited by 6
“Pharmacologic and genetic approaches to inhibit mTORC1 activation have shown the involvement of mTOR in the regulation of both glomerular membrane permeability and protein endocytosis in proximal tubule epithelial cells (PTECs) (Vollenbroker et al., 2009; Gödel et al., 2011; Grahammer et al., 2016).”
BackgroundAi, Z., Zhou, S.-S., Wu, S., Hong, Z., Zhang, Y., Wang, M.-F., Yang, Y., & Wu, H. (2020) · Natural Product Communications · doi:10.1177/1934578x20923821 · Cited by 5
“This was the first study to report that Justicidin B inhibited the proliferation of MCs. Mesangial proliferative glomerulonephritis is a very common chronic nephritis disease, and MC proliferation contributes to mesangial matrix homeostasis.33 Mesangial cell proliferation and matrix expansion are biological responses…”
BackgroundInfluentialTranscriptome analysis of primary podocytes reveals novel calcium regulated regulatory networks
Struk, T., Nair, V., Eichinger, F. H., Kretzler, M., Wedlich‐Söldner, R., Bayraktar, S., & Pavenstädt, H. (2020) · The FASEB Journal · doi:10.1096/fj.201902493rr · Cited by 5
Self-citationQi, C., AlSomali, F., Zhong, J., Harris, R. C., Kon, V., Yang, H., & Fogo, A. B. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab014 · Cited by 6
New clues to environmental influences in glomerular disease
Nelson, P. J., & Alpers, C. E. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.214 · Cited by 5
Sestrin 2: a regulator of the glomerular parietal epithelial cell phenotype
Smeets, B., & Huber, T. B. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00435.2014 · Cited by 5
“Experimentally, mTOR inhibition can delay or reverse glomerular diseases (1, 11) and diabetic nephropathy (6), but inhibition of mTOR frequently causes proteinuria in humans (4).”
BackgroundSelf-citationThe role and mechanism of TSC in kidney diseases: a literature review
Luo, Q., Zheng, X., Xu, Y., Fan, Y., Zhang, H., Li, T., Zhang, X., Peng, L., Jiang, X., & Dai, H. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04260-7 · Cited by 5
Old friends form alliance against podocytes
Simons, M., & Huber, T. B. (2011) · Kidney International · doi:10.1038/ki.2011.298 · Cited by 4
Self-citationmTOR in Diabetic Nephropathy and Retinopathy
Fernandes, R., & Reis, F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00001-3 · Cited by 4
Miesen, L., Eymael, J., Sharma, S., Loeven, M. A., Willemsen, B. K., Bakker, M. A. H., Mooren, F., Meyer‐Schwesinger, C., Dijkman, H. B. P. M., Wetzels, J. F. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65352-y · Cited by 6
Could Autophagic Exhaustion Be a Final Common Pathway for Podocytopathy in FSGS?
Venkatachalam, M. A. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014090919 · Cited by 4
The histologic disorders and underlying mechanisms of podocytes during diabetes
Qian, S., Su, H., & Zhang, C. (2022) · Diabetic Nephropathy · doi:10.2478/dine-2022-0021 · Cited by 3
Das, F., Ghosh‐Choudhury, N., Kasinath, B. S., Sharma, K., & Choudhury, G. G. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114116 · Cited by 3
LncRNAs and IgA nephropathy: underlying molecular pathways and clinical applications
Alimohammadi, M., Kahkesh, S., Abbasi, A., Hashemi, M., Khoshnazar, S. M., Taheriazam, A., & Hushmandi, K. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01660-9 · Cited by 4
“Several rat models of chronic kidney disease—including compensatory renal hypertrophy, diabetic nephropathy, polycystic kidney disease, membranous nephropathy, anti-GBM glomerulonephritis, and anti-thy1 glomerulonephritis—have demonstrated activation of the mTOR pathway [80–82].”
Özel, C., Reitmeier, K., Kieckhöfer, E., Abualia, K., Nguyen-Minh, D., Matin, M., Hagmann, H., Coward, R. J., Brähler, S., Antczak, P., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202502934r · Cited by 3
Dietary methionine mitigates immune-mediated damage by enhancing renal clearance of cytokines
Troha, K., Kambhampati, S., Insenga, A., Metallo, C. M., & Ayres, J. S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2025.12.011 · Cited by 5
Naik, A. S., Alakwaa, F., Nair, V., McCown, P. J., Schaub, J. A., Otto, E. A., Menon, R., Annese, F., Choi, Y. J., Hampson, H. E., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci198545 · Cited by 3
Self-citationType I IFN in Glomerular Disease: Scarring beyond the STING
Jiménez‐Uribe, A. P., Mangos, S., & Hahm, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052497 · Cited by 3
“These observations provide an additional link between IFN-I signaling and the development of GD since the loss of mTORC1 in podocytes causes proteinuria associated with glomerular damage [137].”
BackgroundRenal Disease in Obesity, Metabolic Syndrome and Diabesity
Porrini, E., Navarro-Díaz, M., Rodríguez-Rodríguez, R., & SALIDO, E. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-93521-8_5 · Cited by 3
Secondary glomerulonephritis in neurofibromatosis type 1. Two case reports
Orera, A., Lacarra, S., Fernández, L., Gómez, N., Slon, M. F., & Manrique, J. (2019) · Anales del Sistema Sanitario de Navarra · doi:10.23938/assn.0720 · Cited by 3
Tensin 2-deficient nephropathy: mechanosensitive nephropathy, genetic susceptibility
Sasaki, H., & Sasaki, N. (2022) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.22-0031 · Cited by 3
“This mTORC1 activation is associated with podocyte dysfunction in DN [51, 52].”
BackgroundVitamin B3 inhibits apoptosis and promotes autophagy of islet β cells under high glucose stress
ZHANG, Y., Zhou, X., ZHANG, C., Lai, D., LIU, D., & Wu, Y. (2023) · Biocell · doi:10.32604/biocell.2023.026429 · Cited by 3
Hyun, J. I., Min, J. W., Lee, H. M., Kim, Y. K., Choi, E. J., & Song, H. C. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.016 · Cited by 3
Proteomic Study of Low-Birth-Weight Nephropathy in Rats
Imasawa, T., Claverol, S., Lacombe, D., Amoêdo, N. D., & Rossignol, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910294 · Cited by 3
Targeting TRPC6 in podocytopathies: Why clinical translation remains a challenge?
Patel, C. A., Patel, S., Patel, S. P., Parmar, D., Beladiya, J., Sundar, S. R., & Jain, M. R. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00766-x · Cited by 4
“While mTOR activity is essential for podocyte homeostasis, hyperactivation-as seen in dia - betic nephropathy-leads to podocyte hypertrophy, endoplas - mic reticulum (ER) stress, and eventual apoptosis [68 ].”
Izzedine, H., Perazella, M. A., Kuruvada, K. M., & Jhaveri, K. D. (2026) · Kidney International · doi:10.1016/j.kint.2026.01.036 · Cited by 2
IgM Hyposialylation Modulates Podocyte Vulnerability in Patients With Idiopathic Nephrotic Syndrome
Spinelli, S., Gaudiano, S., Garbarino, A., Lugani, F., Porta, E. L., Petretto, A., Bartolucci, M., Lavarello, C., Grinovero, N., Musante, I., et al. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106598 · Cited by 3
Tian, L., Wang, Y., Guan, C., Agborbesong, E., Zhou, J. X., Mou, S., & Li, X. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00953-5 · Cited by 2
“Hyperactivation of the PI3K/Akt/mTOR axis represents a central mechanism underlying autophagy inhibition in diabetic kidneys [31, 38].”
The Ebf1 knockout mouse and glomerular maturation
Schmidt-Ott, K. M. (2014) · Kidney International · doi:10.1038/ki.2013.472 · Cited by 2
Akilesh, S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.05403-4 · Cited by 3
Cannabinoid Signaling in the Diabetic Proximal Tubule: Of Mice and Men
Naik, A. S., & Brosius, F. C. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.09.004 · Cited by 2
The CLCA1/TMEM16A/Cl– current axis associates with H2S deficiency in diabetic kidney injury
Lee, H. J., Sun, Y., Das, F., Ju, W., Nair, V., Kevil, C. G., Varadarajan, S., Zhang, G., Choudhury, G. G., Singh, B. B., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174848 · Cited by 2
“We explored the mechanism underlying augmented Tmem16A mRNA translation. mTORC1 activates mRNA translation in diabetic kidney injury (30, 37, 46, 47).”
Self-citationPathogenesis of diabetic microvascular complications
Forbes, J. M., & Harcourt, B. E. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch60 · Cited by 3
Regulation of Renal Hyaluronan in Water Handling : Studies in vivo and in vitro
Stridh, S. (2013) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 2
Endogenous adenine is a potential driver of the cardiovascular-kidney-metabolic syndromePreprint
Tamayo, I. M., Lee, H. J., Aslam, M., Liu, J., Ragi, N., Karanam, V., Maity, S., Saliba, A., Treviño, E., Zheng, H., et al. (2024) · medRxiv · doi:10.1101/2024.08.19.24312277 · Cited by 2
“Kidney disease and heart hypertrophy both involve dysregulation of the mammalian target of rapamycin (mTOR) pathway ( 10, 11 ).”
BackgroundLiu, F., Xu, Z., Chen, G., Xu, X., Cao, H., & Chen, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1445550 · Cited by 1
Recurrent Focal Segmental Glomerulosclerosis Post Renal Transplantation
Díaz, M. A. T., Ballesteros, D. A., Covarrubias, O. L., Rojas, A. V. N., & Salazar, I. D. R. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1006530 · Cited by 3
Tong, L., Batool, F., Chiu, Y.-H., Wu, P. D., Zhou, Y., Ma, X., Atanur, S. S., & Cui, W. (2025) · Stem Cell Reports · doi:10.1016/j.stemcr.2025.102680 · Cited by 1
Mitochondrial integrity modulates mTOR signaling and podocyte function
Özel, C., Abualia, K., Nguyen-Minh, D., Matin, M., Unnersjö‐Jess, D., Höhne, M., Bloch, W., Hagmann, H., Coward, R. J., Brähler, S., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114279 · Cited by 1
“38,39 In this study, both Phb2 pko and Oma1 del mice exhibit elevated baseline mTOR activity, as measured by RPS6 phosphorylation.”
Liao, Z., Wang, W., Zhao, Y., Liu, Y., Qiu, D., & Zhang, Y. (2025) · European Urology Open Science · doi:10.1016/j.euros.2025.12.013 · Cited by 1
“Controlled mTOR activity is of importance for preserving the glomerular function of podocytes [18].”
Srivastava, S. P., Kopasz-Gemmen, O., Kunamneni, A., Thurman, A., Yoshida, S., Ozkan, E. E., Swaroop, V., Nanwani, R., Arora, A., Joshi, A., et al. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-03078-y · Cited by 2
“Streptozotocin was purchased from Sigma.”
Self-citationSuzuki, M., Fukuda, A., Kurimoto, R., Kudo, A., & Shibata, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-49025-w · Cited by 1
“Given that p70S6K is a canonical substrate of mTORC1, S6 phosphorylation is widely used as a downstream readout of mTORC1 signaling in metabolic and renal studies 27,54,55 .”
Lu, K., Lu, C., Hou, Y., Huang, Y., Chang, Y.-T., Zheng, C., & Wu, C. (2026) · Pharmaceuticals · doi:10.3390/ph19060952 · Cited by 3
“In diabetic nephropathy, excessive mTORC1 activation contributes to podocyte injury and impaired autophagic homeostasis, whereas non-diabetic CKD and uremic tubular injury may involve overlapping but not identical mechanisms [75,76].”
Atypical Presentations of Diabetic Nephropathy and Novel Therapies
Imbriano, L. J., Maesaka, J. K., Mattana, J., Shirazian, S., & Jerums, G. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0793-9_8 · Cited by 1
Kuo, J. C.-Y., Gorddard, N., & Stuart‐Harris, R. C. (2015) · Breast Cancer Management · doi:10.2217/bmt.15.6 · Cited by 1
Mitochondrial dysfunction in kidney diseases
Galvan, D. L., & Perico, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819621-2.00005-x · Cited by 1
Organelle Stress and mTOR in Aging-Associated Inflammation
Pani, G. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397803-5.00014-9 · Cited by 1
Genetic aspects of familial focal segmental glomerulosclerosis
Agrawal, S., Prakash, S., & Sharma, R. K. (2014) · Clinical Queries Nephrology · doi:10.1016/j.cqn.2014.06.001 · Cited by 1
The Podocyte in Diabetic Nephropathy: Recent Advances
Welsh, G. I., & Coward, R. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-93521-8_11 · Cited by 1
ACTH4-10 protects the ADR-injured podocytes by stimulating B lymphocytes to secrete interleukin-10
Wang, K., Du, H., Chen, Z., Lü, H., Xu, R., & Xue, D. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106769 · Cited by 1
Sirtuins in diabetes mellitus and diabetic kidney disease
Türkmen, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822467-0.00014-0 · Cited by 1
Tanaka, R., Imamura, R., Matsumura, S., Fukae, S., Taniguchi, A., Nakazawa, S., Yamanaka, K., Namba‐Hamano, T., Kakuta, Y., Takao, T., et al. (2024) · The Nephron journals/Nephron journals · doi:10.1159/000535877 · Cited by 1
Nephrotic syndrome in a child with neurofibromatosis type 1: A case report and literature review
Cheng, B., Yang, H., Huang, L., Liao, P., Peng, F., & Wang, X. (2024) · Nephrology · doi:10.1111/nep.14393 · Cited by 1
“4 Recently, many studies have established the connection between the physiology of podocytes and neurons, both morphologically and functionally.”
Isaka, Y., Kimura, T., Takahashi, A., & Takabatake, Y. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801033-4.00016-3
Role of the podocyte signal-transduction systems in the pathogenesis of diabetic nephropathy
Kaburagi, Y., & Unoki‐Kubota, H. (2011) · Diabetology International · doi:10.1007/s13340-011-0053-8
“Conversely, Gödel [13] analyzed mice lacking podocyte mTORC1 activity by podocyte-specific knockout of Raptor, and demonstrated that loss of podocyte mTORC1 activity also caused albuminuria and progressive glomerulosclerosis.”
Background
Metadata
- Authors
- Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., Wiech, T., Fornoni, A., Nelson, R. G., Kretzler, M., Wanke, R., Pavenstädt, H., Kerjaschki, D., Cohen, C. D., Hall, M. N., Rüegg, M. A., Inoki, K., Walz, G., & Huber, T. B.
- Affiliations
- University of Freiburg (DE)
- Ludwig-Maximilians-Universität München (DE)
- University of Zurich (CH)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) (DE)
- University of Miami (US)
- National Institutes of Health (US)
- University of Münster (DE)
- Medical University of Vienna (AT)
- University of Basel (CH)
- Life Sciences Institute (SG)
- Corresponding author
- Huber, Tobias B.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2011-06-01
- Volume
- 121
- Issue
- 6
- Pages
- 2197-2209
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3104746
- OpenAlex
- W2051719011
- Cited by
- 547
- References
- 62
- Citations by year
- 2026: 22 · 2025: 23 · 2024: 28 · 2023: 36 · 2022: 30 · 2021: 43 · 2020: 50 · 2019: 39 · 2018: 40 · 2017: 34 · 2016: 38 · 2015: 36 · 2014: 40 · 2013: 47 · 2012: 25
- FWCI
- 31.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- edoc (University of Basel) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (122439)
- National Institutes of Health (5r01dk083491-09)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK083491, P30DK081943, DK-083491, R01DK124709)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- mTOR, mTORC1, mTORC2, podocytes, diabetic nephropathy, glomerulosclerosis, proteinuria, glomerular hypertrophy, hyperfiltration, mTOR inhibition, glomerular disease, gene deletion
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Regulatory-Associated Protein of mTOR, Rapamycin-Insensitive Companion of mTOR Protein, Adult, Animals, Carrier Proteins, Diabetes Mellitus, Experimental, Diabetic Nephropathies, Humans, Kidney Glomerulus, Mice, Inbred C57BL, Mice, Inbred ICR, Mice, Transgenic, Nephrosis, Lipoid, Proteins, Proteinuria, Transcription Factors, Trans-Activators, Mice, Knockout, Disease Progression, Gene Dosage, Genetic Predisposition to Disease, Sirolimus, Multiprotein Complexes, Adaptor Proteins, Signal Transducing, Podocytes, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.